CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Syntocinon +1 moredrug
Likely dose
Syntocinon 24 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01183221
NCT01183221Phase 2Completed
CompareCT.gov

The Effects of Oxytocin on Complex Social Cognition in Autism Spectrum Disorders

Alexander Kolevzon·interventional·Posted Aug 17, 2010·Updated Apr 15, 2021

In Brief

A Phase 2 clinical trial evaluating Syntocinon and Placebo for Autism and ASD. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This study examines the effects of a single dose of intranasal oxytocin (vs. placebo) on complex social cognition in adults with autism spectrum disorders.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutism, ASD
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 17, 2010
Enrollment StartJun 18, 2010
Primary CompletionApr 25, 2014
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 15.9 years ago

Interventions

Syntocinondrug

One dose of 24 IU (3 sprays/nostril)

Placebodrug

Intranasal Placebo